Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Advances on the Structure of the R2TP/Prefoldin-like Complex.

Muñoz-Hernández H, Pal M, Rodríguez CF, Prodromou C, Pearl LH, Llorca O.

Adv Exp Med Biol. 2018;1106:73-83. doi: 10.1007/978-3-030-00737-9_5.

PMID:
30484153
2.

Author Correction: RPAP3 provides a flexible scaffold for coupling HSP90 to the human R2TP co-chaperone complex.

Martino F, Pal M, Muñoz-Hernández H, Rodríguez CF, Núñez-Ramírez R, Gil-Carton D, Degliesposti G, Skehel JM, Roe SM, Prodromou C, Pearl LH, Llorca O.

Nat Commun. 2018 Jul 31;9(1):3063. doi: 10.1038/s41467-018-05546-1.

3.

Dihydropyridines Allosterically Modulate Hsp90 Providing a Novel Mechanism for Heat Shock Protein Co-induction and Neuroprotection.

Roe MS, Wahab B, Török Z, Horváth I, Vigh L, Prodromou C.

Front Mol Biosci. 2018 Jun 7;5:51. doi: 10.3389/fmolb.2018.00051. eCollection 2018.

4.

RPAP3 provides a flexible scaffold for coupling HSP90 to the human R2TP co-chaperone complex.

Martino F, Pal M, Muñoz-Hernández H, Rodríguez CF, Núñez-Ramírez R, Gil-Carton D, Degliesposti G, Skehel JM, Roe SM, Prodromou C, Pearl LH, Llorca O.

Nat Commun. 2018 Apr 16;9(1):1501. doi: 10.1038/s41467-018-03942-1. Erratum in: Nat Commun. 2018 Jul 31;9(1):3063.

5.

In vivo bioassay to test the pathogenicity of missense human AIP variants.

Aflorei ED, Klapholz B, Chen C, Radian S, Dragu AN, Moderau N, Prodromou C, Ribeiro PS, Stanewsky R, Korbonits M.

J Med Genet. 2018 Aug;55(8):522-529. doi: 10.1136/jmedgenet-2017-105191. Epub 2018 Apr 9.

6.

Multi-chaperone function modulation and association with cytoskeletal proteins are key features of the function of AIP in the pituitary gland.

Hernández-Ramírez LC, Morgan RML, Barry S, D'Acquisto F, Prodromou C, Korbonits M.

Oncotarget. 2018 Jan 11;9(10):9177-9198. doi: 10.18632/oncotarget.24183. eCollection 2018 Feb 6.

7.

The Stoichiometric Interaction of the Hsp90-Sgt1-Rar1 Complex by CD and SRCD Spectroscopy.

Siligardi G, Zhang M, Prodromou C.

Front Mol Biosci. 2018 Jan 17;4:95. doi: 10.3389/fmolb.2017.00095. eCollection 2017.

8.

The integrity and organization of the human AIPL1 functional domains is critical for its role as a HSP90-dependent co-chaperone for rod PDE6.

Sacristan-Reviriego A, Bellingham J, Prodromou C, Boehm AN, Aichem A, Kumaran N, Bainbridge J, Michaelides M, van der Spuy J.

Hum Mol Genet. 2018 Apr 1;27(7):1309. doi: 10.1093/hmg/ddy024. No abstract available.

9.

Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients.

Woodford MR, Sager RA, Marris E, Dunn DM, Blanden AR, Murphy RL, Rensing N, Shapiro O, Panaretou B, Prodromou C, Loh SN, Gutmann DH, Bourboulia D, Bratslavsky G, Wong M, Mollapour M.

EMBO J. 2017 Dec 15;36(24):3650-3665. doi: 10.15252/embj.201796700. Epub 2017 Nov 10.

10.

Differential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System.

Hallett ST, Pastok MW, Morgan RML, Wittner A, Blundell KLIM, Felletar I, Wedge SR, Prodromou C, Noble MEM, Pearl LH, Endicott JA.

Cell Rep. 2017 Oct 31;21(5):1386-1398. doi: 10.1016/j.celrep.2017.10.042.

11.

The integrity and organization of the human AIPL1 functional domains is critical for its role as a HSP90-dependent co-chaperone for rod PDE6.

Sacristan-Reviriego A, Bellingham J, Prodromou C, Boehm AN, Aichem A, Kumaran N, Bainbridge J, Michaelides M, van der Spuy J.

Hum Mol Genet. 2017 Nov 15;26(22):4465-4480. doi: 10.1093/hmg/ddx334. Erratum in: Hum Mol Genet. 2018 Apr 1;27(7):1309.

12.

The Structure of the R2TP Complex Defines a Platform for Recruiting Diverse Client Proteins to the HSP90 Molecular Chaperone System.

Rivera-Calzada A, Pal M, Muñoz-Hernández H, Luque-Ortega JR, Gil-Carton D, Degliesposti G, Skehel JM, Prodromou C, Pearl LH, Llorca O.

Structure. 2017 Jul 5;25(7):1145-1152.e4. doi: 10.1016/j.str.2017.05.016. Epub 2017 Jun 22.

13.

HECTD3 Mediates an HSP90-Dependent Degradation Pathway for Protein Kinase Clients.

Li Z, Zhou L, Prodromou C, Savic V, Pearl LH.

Cell Rep. 2017 Jun 20;19(12):2515-2528. doi: 10.1016/j.celrep.2017.05.078.

14.

Regulatory Mechanisms of Hsp90.

Prodromou C.

Biochem Mol Biol J. 2017 Jan 30;3(1):2. doi: 10.21767/2471-8084.100030.

15.

The structure of FKBP38 in complex with the MEEVD tetratricopeptide binding-motif of Hsp90.

Blundell KL, Pal M, Roe SM, Pearl LH, Prodromou C.

PLoS One. 2017 Mar 9;12(3):e0173543. doi: 10.1371/journal.pone.0173543. eCollection 2017.

16.

Mechanisms of Hsp90 regulation.

Prodromou C.

Biochem J. 2016 Aug 15;473(16):2439-52. doi: 10.1042/BCJ20160005. Review.

17.

The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding.

Woodford MR, Dunn DM, Blanden AR, Capriotti D, Loiselle D, Prodromou C, Panaretou B, Hughes PF, Smith A, Ackerman W, Haystead TA, Loh SN, Bourboulia D, Schmidt LS, Marston Linehan W, Bratslavsky G, Mollapour M.

Nat Commun. 2016 Jun 29;7:12037. doi: 10.1038/ncomms12037.

18.

Cooperation of local motions in the Hsp90 molecular chaperone ATPase mechanism.

Schulze A, Beliu G, Helmerich DA, Schubert J, Pearl LH, Prodromou C, Neuweiler H.

Nat Chem Biol. 2016 Aug;12(8):628-35. doi: 10.1038/nchembio.2111. Epub 2016 Jun 20.

19.

Rapid Proteasomal Degradation of Mutant Proteins Is the Primary Mechanism Leading to Tumorigenesis in Patients With Missense AIP Mutations.

Hernández-Ramírez LC, Martucci F, Morgan RM, Trivellin G, Tilley D, Ramos-Guajardo N, Iacovazzo D, D'Acquisto F, Prodromou C, Korbonits M.

J Clin Endocrinol Metab. 2016 Aug;101(8):3144-54. doi: 10.1210/jc.2016-1307. Epub 2016 Jun 2.

20.

Dihydropyridine Derivatives Modulate Heat Shock Responses and have a Neuroprotective Effect in a Transgenic Mouse Model of Alzheimer's Disease.

Kasza Á, Hunya Á, Frank Z, Fülöp F, Török Z, Balogh G, Sántha M, Bálind Á, Bernáth S, Blundell KL, Prodromou C, Horváth I, Zeiler HJ, Hooper PL, Vigh L, Penke B.

J Alzheimers Dis. 2016 May 7;53(2):557-71. doi: 10.3233/JAD-150860.

21.

Mps1 Mediated Phosphorylation of Hsp90 Confers Renal Cell Carcinoma Sensitivity and Selectivity to Hsp90 Inhibitors.

Woodford MR, Truman AW, Dunn DM, Jensen SM, Cotran R, Bullard R, Abouelleil M, Beebe K, Wolfgeher D, Wierzbicki S, Post DE, Caza T, Tsutsumi S, Panaretou B, Kron SJ, Trepel JB, Landas S, Prodromou C, Shapiro O, Stetler-Stevenson WG, Bourboulia D, Neckers L, Bratslavsky G, Mollapour M.

Cell Rep. 2016 Feb 2;14(4):872-884. doi: 10.1016/j.celrep.2015.12.084. Epub 2016 Jan 21.

22.

c-Abl Mediated Tyrosine Phosphorylation of Aha1 Activates Its Co-chaperone Function in Cancer Cells.

Dunn DM, Woodford MR, Truman AW, Jensen SM, Schulman J, Caza T, Remillard TC, Loiselle D, Wolfgeher D, Blagg BS, Franco L, Haystead TA, Daturpalli S, Mayer MP, Trepel JB, Morgan RM, Prodromou C, Kron SJ, Panaretou B, Stetler-Stevenson WG, Landas SK, Neckers L, Bratslavsky G, Bourboulia D, Mollapour M.

Cell Rep. 2015 Aug 11;12(6):1006-18. doi: 10.1016/j.celrep.2015.07.004. Epub 2015 Jul 30.

23.

Tah1 helix-swap dimerization prevents mixed Hsp90 co-chaperone complexes.

Morgan RM, Pal M, Roe SM, Pearl LH, Prodromou C.

Acta Crystallogr D Biol Crystallogr. 2015 May;71(Pt 5):1197-206. doi: 10.1107/S1399004715004551. Epub 2015 Apr 25.

24.

Structural basis for phosphorylation-dependent recruitment of Tel2 to Hsp90 by Pih1.

Pal M, Morgan M, Phelps SE, Roe SM, Parry-Morris S, Downs JA, Polier S, Pearl LH, Prodromou C.

Structure. 2014 Jun 10;22(6):805-18. doi: 10.1016/j.str.2014.04.001. Epub 2014 May 1.

25.

Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors.

Mollapour M, Bourboulia D, Beebe K, Woodford MR, Polier S, Hoang A, Chelluri R, Li Y, Guo A, Lee MJ, Fotooh-Abadi E, Khan S, Prince T, Miyajima N, Yoshida S, Tsutsumi S, Xu W, Panaretou B, Stetler-Stevenson WG, Bratslavsky G, Trepel JB, Prodromou C, Neckers L.

Mol Cell. 2014 Jan 23;53(2):317-29. doi: 10.1016/j.molcel.2013.12.007.

26.

Synthesis of macrolactam analogues of radicicol and their binding to heat shock protein Hsp90.

Dutton BL, Kitson RR, Parry-Morris S, Roe SM, Prodromou C, Moody CJ.

Org Biomol Chem. 2014 Feb 28;12(8):1328-40. doi: 10.1039/c3ob42211a.

PMID:
24435512
27.

Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins.

Smith JR, de Billy E, Hobbs S, Powers M, Prodromou C, Pearl L, Clarke PA, Workman P.

Oncogene. 2015 Jan 2;34(1):15-26. doi: 10.1038/onc.2013.519. Epub 2013 Dec 2.

28.

Posttranslational modification and conformational state of heat shock protein 90 differentially affect binding of chemically diverse small molecule inhibitors.

Beebe K, Mollapour M, Scroggins B, Prodromou C, Xu W, Tokita M, Taldone T, Pullen L, Zierer BK, Lee MJ, Trepel J, Buchner J, Bolon D, Chiosis G, Neckers L.

Oncotarget. 2013 Jul;4(7):1065-74.

29.

Synthesis of 19-substituted geldanamycins with altered conformations and their binding to heat shock protein Hsp90.

Kitson RR, Chang CH, Xiong R, Williams HE, Davis AL, Lewis W, Dehn DL, Siegel D, Roe SM, Prodromou C, Ross D, Moody CJ.

Nat Chem. 2013 Apr;5(4):307-14. doi: 10.1038/nchem.1596. Epub 2013 Mar 10.

30.

ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system.

Polier S, Samant RS, Clarke PA, Workman P, Prodromou C, Pearl LH.

Nat Chem Biol. 2013 May;9(5):307-12. doi: 10.1038/nchembio.1212. Epub 2013 Mar 17. Erratum in: Nat Chem Biol. 2013 Jun;9(6):406.

31.

Structure of the TPR domain of AIP: lack of client protein interaction with the C-terminal α-7 helix of the TPR domain of AIP is sufficient for pituitary adenoma predisposition.

Morgan RM, Hernández-Ramírez LC, Trivellin G, Zhou L, Roe SM, Korbonits M, Prodromou C.

PLoS One. 2012;7(12):e53339. doi: 10.1371/journal.pone.0053339. Epub 2012 Dec 31.

32.

CDK-dependent Hsp70 Phosphorylation controls G1 cyclin abundance and cell-cycle progression.

Truman AW, Kristjansdottir K, Wolfgeher D, Hasin N, Polier S, Zhang H, Perrett S, Prodromou C, Jones GW, Kron SJ.

Cell. 2012 Dec 7;151(6):1308-18. doi: 10.1016/j.cell.2012.10.051.

33.

Co-crystalization and in vitro biological characterization of 5-aryl-4-(5-substituted-2-4-dihydroxyphenyl)-1,2,3-thiadiazole Hsp90 inhibitors.

Sharp SY, Roe SM, Kazlauskas E, Cikotienė I, Workman P, Matulis D, Prodromou C.

PLoS One. 2012;7(9):e44642. doi: 10.1371/journal.pone.0044642. Epub 2012 Sep 11.

34.

Dynamic tyrosine phosphorylation modulates cycling of the HSP90-P50(CDC37)-AHA1 chaperone machine.

Xu W, Mollapour M, Prodromou C, Wang S, Scroggins BT, Palchick Z, Beebe K, Siderius M, Lee MJ, Couvillon A, Trepel JB, Miyata Y, Matts R, Neckers L.

Mol Cell. 2012 Aug 10;47(3):434-43. doi: 10.1016/j.molcel.2012.05.015. Epub 2012 Jun 21.

35.

Charged linker sequence modulates eukaryotic heat shock protein 90 (Hsp90) chaperone activity.

Tsutsumi S, Mollapour M, Prodromou C, Lee CT, Panaretou B, Yoshida S, Mayer MP, Neckers LM.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2937-42. doi: 10.1073/pnas.1114414109. Epub 2012 Feb 6.

36.

Targeting the Hsp90 molecular chaperone with novel macrolactams. Synthesis, structural, binding, and cellular studies.

Day JE, Sharp SY, Rowlands MG, Aherne W, Hayes A, Raynaud FI, Lewis W, Roe SM, Prodromou C, Pearl LH, Workman P, Moody CJ.

ACS Chem Biol. 2011 Dec 16;6(12):1339-47. doi: 10.1021/cb200196e. Epub 2011 Oct 4.

PMID:
21932796
37.

The 'active life' of Hsp90 complexes.

Prodromou C.

Biochim Biophys Acta. 2012 Mar;1823(3):614-23. doi: 10.1016/j.bbamcr.2011.07.020. Epub 2011 Aug 4. Review.

38.

Features of the Streptomyces hygroscopicus HtpG reveal how partial geldanamycin resistance can arise with mutation to the ATP binding pocket of a eukaryotic Hsp90.

Millson SH, Chua CS, Roe SM, Polier S, Solovieva S, Pearl LH, Sim TS, Prodromou C, Piper PW.

FASEB J. 2011 Nov;25(11):3828-37. doi: 10.1096/fj.11-188821. Epub 2011 Jul 21.

PMID:
21778327
39.

A combinatorial method to enable detailed investigation of protein-protein interactions.

Maclagan K, Tommasi R, Laurine E, Prodromou C, Driscoll PC, Pearl LH, Reich S, Savva R.

Future Med Chem. 2011 Mar;3(3):271-82. doi: 10.4155/fmc.10.289.

PMID:
21446842
40.

Threonine 22 phosphorylation attenuates Hsp90 interaction with cochaperones and affects its chaperone activity.

Mollapour M, Tsutsumi S, Truman AW, Xu W, Vaughan CK, Beebe K, Konstantinova A, Vourganti S, Panaretou B, Piper PW, Trepel JB, Prodromou C, Pearl LH, Neckers L.

Mol Cell. 2011 Mar 18;41(6):672-81. doi: 10.1016/j.molcel.2011.02.011.

41.

Cerebral abnormalities in infants with myelomeningocele.

Alexiou GA, Zarifi MK, Georgoulis G, Mpouza E, Prodromou C, Moutafi A, Anagnostakou M, Sfakianos G, Prodromou N.

Neurol Neurochir Pol. 2011 Jan-Feb;45(1):18-23.

PMID:
21384289
42.

Malignant progression of a pleomorphic xanthoastrocytoma in a child.

Alexiou GA, Moschovi M, Stefanaki K, Prodromou C, Sfakianos G, Prodromou N.

Neuropediatrics. 2010 Aug;41(2):69-71. doi: 10.1055/s-0030-1255094. Epub 2010 Aug 26.

PMID:
20799153
43.

Structural basis for assembly of Hsp90-Sgt1-CHORD protein complexes: implications for chaperoning of NLR innate immunity receptors.

Zhang M, Kadota Y, Prodromou C, Shirasu K, Pearl LH.

Mol Cell. 2010 Jul 30;39(2):269-81. doi: 10.1016/j.molcel.2010.05.010.

44.

Inhibition of Hsp90 with resorcylic acid macrolactones: synthesis and binding studies.

Day JE, Sharp SY, Rowlands MG, Aherne W, Lewis W, Roe SM, Prodromou C, Pearl LH, Workman P, Moody CJ.

Chemistry. 2010 Sep 10;16(34):10366-72. doi: 10.1002/chem.201001119.

PMID:
20661961
45.

Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function.

Mollapour M, Tsutsumi S, Donnelly AC, Beebe K, Tokita MJ, Lee MJ, Lee S, Morra G, Bourboulia D, Scroggins BT, Colombo G, Blagg BS, Panaretou B, Stetler-Stevenson WG, Trepel JB, Piper PW, Prodromou C, Pearl LH, Neckers L.

Mol Cell. 2010 Feb 12;37(3):333-43. doi: 10.1016/j.molcel.2010.01.005.

46.

Detection of the ATPase activity of the molecular chaperones Hsp90 and Hsp72 using the TranscreenerTM ADP assay kit.

Rowlands M, McAndrew C, Prodromou C, Pearl L, Kalusa A, Jones K, Workman P, Aherne W.

J Biomol Screen. 2010 Mar;15(3):279-86. doi: 10.1177/1087057109360253. Epub 2010 Feb 10.

PMID:
20147598
47.

A simple yeast-based system for analyzing inhibitor resistance in the human cancer drug targets Hsp90alpha/beta.

Millson SH, Prodromou C, Piper PW.

Biochem Pharmacol. 2010 Jun 1;79(11):1581-8. doi: 10.1016/j.bcp.2010.01.031. Epub 2010 Feb 4.

PMID:
20138026
48.

Strategies for stalling malignancy: targeting cancer's addiction to Hsp90.

Prodromou C.

Curr Top Med Chem. 2009;9(15):1352-68. Review.

PMID:
19860736
49.

Hsp90 charged-linker truncation reverses the functional consequences of weakened hydrophobic contacts in the N domain.

Tsutsumi S, Mollapour M, Graf C, Lee CT, Scroggins BT, Xu W, Haslerova L, Hessling M, Konstantinova AA, Trepel JB, Panaretou B, Buchner J, Mayer MP, Prodromou C, Neckers L.

Nat Struct Mol Biol. 2009 Nov;16(11):1141-7. doi: 10.1038/nsmb.1682. Epub 2009 Oct 18.

PMID:
19838189
50.

Structural-thermodynamic relationships of interactions in the N-terminal ATP-binding domain of Hsp90.

Nilapwar S, Williams E, Fu C, Prodromou C, Pearl LH, Williams MA, Ladbury JE.

J Mol Biol. 2009 Oct 2;392(4):923-36. doi: 10.1016/j.jmb.2009.07.041. Epub 2009 Jul 21.

PMID:
19631219

Supplemental Content

Loading ...
Support Center